D-1490-2019 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-1490-2019 was initiated by Lupin Pharmaceuticals Inc. on Jul 11, 2019 and is designated Class III. Reason for recall: Labeling: Missing label; Product complaints reported missing bottle label. The recall status is terminated (terminated Sep 9, 2020). Affected quantity: 17,238 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 24, 2019
Initiation Date
Jul 11, 2019
Termination Date
Sep 9, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
17,238 bottles

Product description

Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL Bottle, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, India, NDC 68180-435-01.

Reason for recall

Labeling: Missing label; Product complaints reported missing bottle label.

Distribution pattern

Nationwide in the U.S. and PR.

Code information

Lot #: H805157, Exp. 05/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1490-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1490-2019. Report a data issue: hello@regdatalab.com.